Klugman K - Search Results

1

Antibiotic therapy of community respiratory tract infections: strategies for optimal outcomes and minimized resistance emergence.

Ball P, Baquero F, Cars O, File T, Garau J, Klugman K, Low DE, Rubinstein E, Wise R; Consensus Group on Resistance and Prescribing in Respiratory Tract Infection. Ball P, et al. Among authors: klugman k. J Antimicrob Chemother. 2002 Jan;49(1):31-40. doi: 10.1093/jac/49.1.31. J Antimicrob Chemother. 2002. PMID: 11751764 Review.

2

Evidence to support the rationale that bacterial eradication in respiratory tract infection is an important aim of antimicrobial therapy.

Dagan R, Klugman KP, Craig WA, Baquero F. Dagan R, et al. Among authors: klugman kp. J Antimicrob Chemother. 2001 Feb;47(2):129-40. doi: 10.1093/jac/47.2.129. J Antimicrob Chemother. 2001. PMID: 11157895 Review.

3

Surveillance of resistance in bacteria causing community-acquired respiratory tract infections.

Felmingham D, Feldman C, Hryniewicz W, Klugman K, Kohno S, Low DE, Mendes C, Rodloff AC. Felmingham D, et al. Among authors: klugman k. Clin Microbiol Infect. 2002;8 Suppl 2:12-42. doi: 10.1046/j.1469-0691.8.s.2.5.x. Clin Microbiol Infect. 2002. PMID: 12427206 Free article. Review.

4

Community-acquired pneumonia: new management strategies for evolving pathogens and antimicrobial susceptibilities.

Klugman KP, Low DE, Metlay J, Pechere JC, Weiss K. Klugman KP, et al. Int J Antimicrob Agents. 2004 Nov;24(5):411-22. doi: 10.1016/j.ijantimicag.2004.08.006. Int J Antimicrob Agents. 2004. PMID: 15519470 Review.

5

Future trends in antimicrobial chemotherapy: expert opinion on the 43rd ICAAC.

Ball AP, Bartlett JG, Craig WA, Drusano GL, Felmingham D, Garau JA, Klugman KP, Low DE, Mandell LA, Rubinstein E, Tillotson GS. Ball AP, et al. Among authors: klugman kp. J Chemother. 2004 Oct;16(5):419-36. doi: 10.1179/joc.2004.16.5.419. J Chemother. 2004. PMID: 15565907 Review.

6

High-level telithromycin resistance in a clinical isolate of Streptococcus pneumoniae.

Wolter N, Smith AM, Low DE, Klugman KP. Wolter N, et al. Antimicrob Agents Chemother. 2007 Mar;51(3):1092-5. doi: 10.1128/AAC.01153-06. Epub 2007 Jan 8. Antimicrob Agents Chemother. 2007. PMID: 17210764 Free PMC article.

7

The battle against emerging antibiotic resistance: should fluoroquinolones be used to treat children?

Mandell LA, Peterson LR, Wise R, Hooper D, Low DE, Schaad UB, Klugman KP, Courvalin P. Mandell LA, et al. Clin Infect Dis. 2002 Sep 15;35(6):721-7. doi: 10.1086/341900. Epub 2002 Aug 20. Clin Infect Dis. 2002. PMID: 12203170

8

A disease model descriptive of progression between chronic obstructive pulmonary disease exacerbations and community-acquired pneumonia: roles for underlying lung disease and the pharmacokinetics/pharmacodynamics of the antibiotic.

File TM Jr, Monte SV, Schentag JJ, Paladino JA, Klugman KP, Lavin B, Yu VL, Singer ME, Adelman MH. File TM Jr, et al. Int J Antimicrob Agents. 2009 Jan;33(1):58-64. doi: 10.1016/j.ijantimicag.2008.07.019. Epub 2008 Oct 1. Int J Antimicrob Agents. 2009. PMID: 18835762

9

Fluoroquinolone-resistant Streptococcus pneumoniae, an emerging but unrecognized public health concern: is it time to resight the goalposts?

Ambrose PG, Bast D, Doern GV, Iannini PB, Jones RN, Klugman KP, Low DE. Ambrose PG, et al. Among authors: klugman kp. Clin Infect Dis. 2004 Nov 15;39(10):1554-6; author reply 1556-7. doi: 10.1086/425508. Clin Infect Dis. 2004. PMID: 15546106 No abstract available.

10

Clinical impact of antibiotic resistance in respiratory tract infections.

Klugman KP. Klugman KP. Int J Antimicrob Agents. 2007 Feb;29 Suppl 1:S6-10. doi: 10.1016/S0924-8579(07)70004-3. Int J Antimicrob Agents. 2007. PMID: 17307654 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

554 results

Search Page